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Cellular/Molecular

Kappa Opioid Receptor-Induced Aversion Requires p38
MAPK Activation in VTA Dopamine Neurons
Jonathan M. Ehrich,1,2 Daniel I. Messinger,2 Cerise R. Knakal,3 Jamie R. Kuhar,2 Selena S. Schattauer,2
Michael R. Bruchas,2 Larry S. Zweifel,1,2,3 Brigitte L. Kieffer,4 Paul E.M. Phillips,1,2,3 and Charles Chavkin1,2
1Graduate Program in Neurobiology and Behavior, 2Department of Pharmacology, and 3Department of Psychiatry and Behavioral Sciences, University of
Washington, Seattle, Washington 98195, and 4Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique/
Institut National de la Santé et de la Recherche Médicale/Université de Strasbourg, Illkirch, France

The endogenous dynorphin- opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls the
risk of depression-like and addiction behaviors; however, the molecular and neural circuit mechanisms are not understood. In this study,
we report that KOR activation of p38␣ MAPK in ventral tegmental (VTA) dopaminergic neurons was required for conditioned place
aversion (CPA) in mice. Conditional genetic deletion of floxed KOR or floxed p38␣ MAPK by Cre recombinase expression in dopaminergic neurons blocked place aversion to the KOR agonist U50,488. Selective viral rescue by wild-type KOR expression in dopaminergic
neurons of KOR ⫺/⫺ mice restored U50,488-CPA, whereas expression of a mutated form of KOR that could not initiate p38␣ MAPK
activation did not. Surprisingly, while p38␣ MAPK inactivation blocked U50,488-CPA, p38␣ MAPK was not required for KOR inhibition
of evoked dopamine release measured by fast scan cyclic voltammetry in the nucleus accumbens. In contrast, KOR activation acutely
inhibited VTA dopaminergic neuron firing, and repeated exposure attenuated the opioid response. This adaptation to repeated exposure
was blocked by conditional deletion of p38␣ MAPK, which also blocked KOR-induced tyrosine phosphorylation of the inwardly rectifying
potassium channel (GIRK) subunit Kir3.1 in VTA dopaminergic neurons. Consistent with the reduced response, GIRK phosphorylation
at this amino terminal tyrosine residue (Y12) enhances channel deactivation. Thus, contrary to prevailing expectations, these results
suggest that  opioid-induced aversion requires regulation of VTA dopaminergic neuron somatic excitability through a p38␣ MAPK
effect on GIRK deactivation kinetics rather than by presynaptically inhibiting dopamine release.
Key words: depression; dopamine; dynorphin; GIRK; kappa opioid receptor; stress

Significance Statement
Kappa opioid receptor (KOR) agonists have the potential to be effective, nonaddictive analgesics, but their therapeutic utility is
greatly limited by adverse effects on mood. Understanding how KOR activation produces dysphoria is key to the development of
better analgesics and to defining how the endogenous dynorphin opioids produce their depression-like effects. Results in this
study show that the aversive effects of  receptor activation required arrestin-dependent p38␣ MAPK activation in dopamine
neurons but did not require inhibition of dopamine release in the nucleus accumbens. Thus, contrary to the prevailing view,
inhibition of mesolimbic dopamine release does not mediate the aversive effects of KOR activation and functionally selective 
opioids that do not activate arrestin signaling may be effective analgesics lacking dysphoric effects.

Stress exposure has profound effects on mood and drug abuse
risk (Kendler et al., 1999; Brady and Sinha, 2005). Uncontrolled,

sustained stressful experiences increase depressive and anxiety
disorders in humans and in animal models of these behaviors
(Neumann et al., 2011; Kormos and Gaszner, 2013). Stress expo-
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sure also increases the rewarding valence of drugs of abuse, promotes escalation of addictive drug consumption, and stimulates
relapse in abstinent individuals (Brady and Sinha, 2005; Mantsch
et al., 2015). Developing proresilience medications based on an
understanding of how stress controls these behaviors has the potential for a novel therapeutic advance. Key to this understanding
is the analysis of how stress-evoked release of neurotransmitters
affects neural circuit physiology and decision-making processes.
A series of recent studies indicate that stress exposure produces its
dysphoric, anxiogenic, and proaddictive effects through the activation of extrahypothalamic cortocotrophin releasing factor,
which releases the endogenous dynorphin opioid neuropeptides
in brain (Land et al., 2008; Mantsch et al., 2015). Dynorphin
selectively activates  opioid receptors (KOR), and rodents
treated with  receptor antagonists or genetically lacking either
prodynorphin or KOR have reduced immobility in forced swim
assays (typical of antidepressant drug actions), reduced social
avoidance behaviors following repeated social defeat, reduced
escalation of psychostimulant self-administration, and reduced reinstatement of extinguished ethanol or cocaine selfadministration (Bruchas et al., 2010; Van’t Veer and Carlezon,
2013; Lalanne et al., 2014). Recent clinical studies confirm that
drugs having KOR antagonist activity significantly reduce depressive symptoms in humans with treatment-resistant depression and reduce nicotine consumption in dependent individuals
(Ehrich et al., 2015; Saxon et al., 2015).
Pharmacological activation of KOR in humans evokes reports
of dysphoria and anxiety similar to those detected in rodent models (Pfeiffer et al., 1986; Millan, 1990; Vortherms and Roth, 2006).
At the circuit level, KOR activation in the serotonergic neurons of
dorsal raphe nucleus (DRN), the dopaminergic neurons of the
ventral tegmental area (VTA), and neurons of the nucleus accumbens (NAc) have been implicated in the aversive properties
of the stress response (Bruchas et al., 2010; Van’t Veer and Carlezon, 2013). These results suggest that dynorphin regulates
mood by controlling serotonergic and dopaminergic inputs to
the NAc, but these circuit mechanisms are not yet clear. At the
molecular level, KOR activation stimulates Gi/o protein signaling
that reduces neuronal activity by increasing potassium conductance, decreasing voltage activated calcium conductance, and inhibiting transmitter vesicle release (Bruchas et al., 2010). In
addition, sustained KOR activation recruits arrestin-dependent
signaling, which activates p38 mitogen-activated protein kinase
(MAPK) signaling (Chavkin et al., 2014). Pharmacological
inhibition of p38 MAPK, genetic block of KOR-dependent
p38 MAPK activation by G-protein-coupled receptor kinase 3
(GRK3) deletion, or cell-specific deletion of p38␣ MAPK in serotonergic neurons blocks stress-induced aversion (Bruchas et
al., 2011; Chavkin et al., 2014). The separation between the receptor signaling pathways controlling G-protein-mediated responses and arrestin-mediated responses have important
implications for drug development in general, but within the
KOR system specifically, these findings predict that a G-biased
KOR agonist would have analgesic efficacy without the dysphoric
properties of conventional KOR agonists (Chavkin, 2011). Finding a noneuphorigenic (thus nonaddictive) opioid analgesic has
been a central goal of opioid medicinal chemistry for ⬎100 years,
but the prediction that G-biased KOR agonists that do not activate p38 MAPK signaling would not be dysphoric requires that
we understand how activation of KOR either pharmacologically
or by stress-induced dynorphin release produces dysphoria.
Di Chiara and Imperato (1988) originally noted that KOR
agonists inhibited dopamine release measured by in vivo micro-
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dialysis in the striatum, and suggested that dysphoria was a consequence of reduced dopamine tone. This hypothesis was
consistent with the prevailing view that euphoric effects of addictive drugs resulted from an elevation of dopamine tone (Wise and
Bozarth, 1982). Subsequent studies by Schultz et al. (1998) provided a more nuanced view of dopamine function, suggesting
that dopamine actually provides a “reward-prediction error signal,” rather than a simple “reward” signal. Thus, how KOR inhibition of dopamine release contributes to dysphoria is not clear,
and reconciling our understanding of KOR activation of p38
MAPK mechanisms and regulation of dopamine release seems
necessary to understand how stress-induced dysphoria is encoded in brain. In the present study, we measured KOR regulation of dopamine release using fast-scan cyclic voltammetry
(FSCV), used Cre recombinase-dependent conditional genetic
deletion of KOR or p38␣ MAPK in VTA dopamine neurons, and
used conditioned place aversion behavioral assays to assess the
mechanisms underlying dynorphin/KOR dependent dysphoria.

Materials and Methods
Animals. Male C57BL/6 mice (Charles River) ⬎50 d old were used and
given ad libitum access to food and water. Conditional knock-out of
p38␣ in dopaminergic neurons was achieved using p38␣ floxed
(Mapk14lox/⫹) mice on C57BL/6 background as previously described
(Bruchas et al., 2011) and crossing them with mice that express Cre
recombinase under the control of the dopamine transporter (DAT,
Slc6a3Cre/⫹), a unique marker for dopaminergic neurons (Zhuang et al.,
2005). Global gene deletion of KOR (Oprk1⫺/⫺) on C57BL/6 background was accomplished as previously described (Hough et al., 2000).
In some instances, conventional KOR gene knock-out mice were bred to
also carry the DAT-Cre transgene. Conditional gene knock-out of KOR
was achieved using a floxed KOR line generated by the Institut Clinique
de la Souris, in which exon 1 of KOR was flanked by loxP sites. This exon
was then selectively excised in dopaminergic neurons by crossing to the
DAT-Cre line and in serotonergic neurons by crossing with the ePet-Cre
line (Scott et al., 2005; Zhuang et al., 2005). All animal procedures
were approved by the University of Washington Institutional Animal
Care and Use Committee.
Genotyping. Genotyping was performed as previously described (Bruchas
et al., 2011). PCR screening was performed using the following primers: A3
(5⬘-ATGAGATGCAGTACCCTTGGAGACCAGAAG-3⬘) and A4 (5⬘-AGC
CAGGGCTATACAGAGAAAAACCCTGTG-3⬘) for the floxed and wildtype (⫹) p38␣ alleles, giving bands of 230 and 180 bp, respectively. Primers
A1 (5⬘-CCACAGAAGAGATGGAGCTATATGGATCTC-3⬘) and A4 were
used to detect the null p38␣⌬ allele as a 420 bp PCR product. The DAT-Cre
and ePet-Cre transgenes were detected using 5⬘-AGCGTTCGAACG
CACTGATTTCG-3⬘ and 5⬘-CGCCGTAAATCAATCGATGAGTTG-3⬘,
yielding a 330 bp band. The ROSA26-yellow fluorescent protein (ROSAYFP) reporter gene was screened for with 5⬘-AAGACCGCGAAG
AGTTTGTC-3⬘, 5⬘-AAAGTCGCTCTGAGTTGTTAT-3⬘, and 5⬘-GGA
GCGGGAGAAATGGATATG-3⬘, giving a 320 bp EYFP and 600 bp wildtype band. For screening of global KOR knock-outs, the wild-type KOR
allele was amplified using 5⬘-AATTGTCTTTTGGCCACTGC-3⬘ and 5⬘GTTGGTTGCGGTCTTCATCT-3⬘ giving a 510 bp band, whereas the null
KOR knock-out allele yielded a 450 bp band when screened in a separate
reaction with 5⬘-AGGAAGCAAAAAGCCTCTCC-3⬘ and 5⬘-CTCGT
CCTGCAGTTCATTCA-3⬘. For the floxed KOR mice, 5⬘-GCACCA
AAGTCAGGGAAGGT-3⬘ and 5⬘CAGGGCATATACTCTTCTCGCT-3⬘
were used to screen for the wild-type and floxed KOR alleles, giving bands of
317 and 427 bp, respectively.
Stereotaxic injection. Mice were anesthetized with isoflurane and
mounted on a model 1900 stereotaxic alignment system (David Kopf
Instruments). For VTA injections, a 32 gauge needle with a 45 degree
beveled tip (Hamilton) was lowered bilaterally (anteroposterior ⫺3.30
mm, mediolateral ⫾0.30 mm from bregma) and 0.5 l was injected at
dorsoventral ⫺4.70 to 4.75 mm and at ⫺4.40 to 4.45 mm from bregma.
For DRN injections, a 25 gauge needle with beveled tip (Hamilton) was
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lowered unilaterally (anteroposterior ⫺4.65 mm, mediolateral 0.00 mm
from bregma) and 1 l was injected at dorsoventral ⫺3.90 to 4.00 mm
from bregma. Injection locations were confirmed via postmortem
immunohistochemistry.
Vector design and production. Lenti-KOR and Lenti-KOR(S369A)
(Lenti-KSA) were developed and produced as previously described
(Land et al., 2008). AAV-DIO KOR-GFP and AAV-DIO KSA-GFP were
developed using the AM/CBA-DIO-poly vector (Cardin et al., 2009). Rat
KOR-GFP or KSA-GFP was subcloned into the AAV-DIO vector using
AgeI and NotI in the reverse coding orientation so that expression would
only be driven in the presence of Cre recombinase under the chicken
␤-actin promoter.
After confirming sequence fidelity, HEK293T cells were transfected
with 10 g AAV and 20 g pDG1 vector per 10 cm plate. Three days after
transfection, cells were harvested and subjected to three freeze–thaw cycles. The supernatant was transferred to a Beckman tube containing a
40% sucrose cushion and spun at 27,000 rpm overnight at 4°C. Pellets
were resuspended in CsCl at a density of 1.37 g/ml and spun at 5000 rpm
overnight at 4°C. The following day, 1 ml CsCl fractions were run on an
agarose gel, and genome-containing fractions were selected and spun
again at 5000 rpm overnight at 4°C. The 1 ml fractions were collected
again, and genome containing fractions were dialyzed overnight. The
filtered solution was transferred to a Beckman tube and spun at 27,000
rpm overnight at 4°C. The pellet (containing purified AAV) was resuspended in 100 l 1⫻ HBSS.
Conditioned place preference (CPP). Mice were trained in a balanced
three-chamber apparatus consisting of chambers of equal size with horizontal or vertical stripes, and a third smaller chamber in the center. The
paradigm consisted of tests on day 1 and four and training on days 2 and
3. On test days, the mice were placed in the center chamber and then
allowed to roam freely through all three chambers for 30 min. Time spent
in each chamber was recorded with a video camera (Canon DC310) and
analyzed using Ethovision (Noldus). On training days, mice received
saline vehicle (10 ml/kg, i.p.) while restricted to one chamber in the
morning and the prototypical  opioid agonist U50,488 (2.5–5.0 mg/kg
at 10 ml/kg, i.p.) or cocaine (15 mg/kg at 10 ml/kg, s.c.) in the other
chamber in the afternoon. The drug-paired chamber was assigned based
on the day 1 pretest to ensure that the average time spent in each chamber
was the same for all groups. The final preference score was determined
based on the difference in the amount of time spent in the drug-paired
chamber on the day 4 post-test and the day 1 pretest. All mice were
handled once or twice a day for 4 d the week before the day 1 pretest. For
cocaine CPP experiments, locomotor activity was recorded and analyzed.
U50,488 locomotor experiments. Following the 4 d U50,488 CPA experiment, on days 5 and 6, a subset of mice were injected with either saline or
U50,488 (10 mg/kg) and allowed to roam the CPP chamber freely. To
allow for a within-subjects comparison, injections were administered in
an alternating fashion such that half of the mice in a given cohort received
each injection on a given day.
Tail-flick analgesia. Mice were held while the tip of their tail was submerged in 52 ⫾ 1°C water, and the tail withdrawal latencies were timed.
Each mouse was exposed twice: once as a baseline and a second time 30
min after administration of 15 mg/kg U50,488.
Immunohistochemistry. Mice were anesthetized with sodium pentobarbital (120 mg/kg, i.p.) and intracardially perfused with ice-cold PBS
and 4% PFA. Brains were stored overnight in 4% PFA, then cryoprotected in 30% sucrose (w/v) in phosphate buffer (PB) solution. At least
48 h later, brains were sliced at 30 m using a microtome (Leica). Slices
were stored at 4°C in PB with 0.1% sodium azide. VTA and DRN slices
were then taken and washed for 3 ⫻ 10 min in PBS before blocking in PBS
containing 5% normal goat serum and 0.3% Triton X-100. Slices were
then incubated for 36 – 48 h in blocking solution containing pairs of the
following primary antibodies: chicken anti-tyrosine hydroxylase (1:1000,
AB9702, Millipore), rabbit anti-KOR (1:1000, from an affinity purified
1.32 g/ml stock) (Drake et al., 1996), chicken anti-GFP (1:3000,
AB13970, Abcam), mouse anti-tyrosine hydroxylase (1:500, T1299,
Sigma), mouse anti-tryptophan hydroxylase (1:500, T0678, Sigma), and
mouse anti-GAD67 (1:1000, MAB5406, Millipore). In addition, we used
a rabbit polyclonal antibody generated against the phosphorylated-Tyr
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12 residue of KIR 3.1 (7.5 g/ml, GIRKp) (Ippolito et al., 2005; Lemos et
al., 2012). The peptide sequence used to generate GIRKp is unique based
on a blast search of the mouse genome, and GIRKp-ir was not evident in
Kir3.1 ⫺/⫺ mice (Ippolito et al., 2005). Standard immunohistochemical
procedures were performed to obtain pY12-KIR 3.1 (GIRKp-ir) and
yellow-fluorescent protein (YFP-ir) (Abcam, chicken polyclonal
ab13970) staining. Slices were then washed for 6 ⫻ 15 min in PBS and
incubated in blocking solution containing Alexa-488 and Alexa-555 (1:
500, Invitrogen) tagged to IgG of the appropriate species. The slices were
then washed for 3 ⫻ 10 min in PBS and 2 ⫻ 10 min in PB. Slices were then
mounted onto Superfrost Plus slides (Fisher) with Vectashield mounting
media and sealed with nail polish for microscopy. All slices were imaged
at the W.M. Keck Center for Advanced Studies in Neural Signaling (Seattle) on either a Leica SL confocal or a Nikon Upright with QImaging
Camera.
GIRKp-ir quantification. For comparisons of GIRKp-ir from different
behavioral treatment groups, two or three animals for each group were
perfused, sectioned, and processed in parallel. Imaging of sections from
animals exposed to different treatments was done at the same time with
the same microscope and camera settings. As different rounds of staining
often yield different immunoreactive (ir) intensities, images from each
treatment group displayed in this study came from the same round of
staining. The patterns of GIRKp-ir seen in the VTA across treatment
groups were similar to that previously reported in the dorsal raphe
(Lemos et al., 2012). The selectivity for dopamine neurons of the DATCre driver present in our control and p38␣ CKO DAT mice has been
shown previously (Zhuang et al., 2005; Bruchas et al., 2011); and as such,
we used YFP staining as a proxy for dopaminergic phenotype to directly
compare Cre-expressing neurons in control and conditional knock-out
mice. We quantified GIRKp-ir in putative dopamine neurons of the VTA
using Photoshop software to calculate the percentage of YFP-ir-positive
cells also displaying GIRKp-ir (i.e., colocalization) in fields imaged at
20⫻ magnification. Cells were considered positive for the protein if the
intensity of the immunoreactivity was 1 SD above the average background pixel intensity for that slice. Images used for quantification were
not adjusted for brightness or contrast. Cell counts and quantification
were performed by an observer blind to treatment and genotype.
Rotarod. Mice were placed on a 4-cm-wide rotating rod (Rotarod,
San Diego Instruments), which accelerated from 4 to 40 rpm over 4
min. The latency to fall off of or clasp onto the rotating rod was
recorded.
In vitro voltammetry. Mice were rapidly decapitated, the brain was
dissected, and slices were prepared as previously described (Lemos et al.,
2012). Microelectrodes were fabricated by pulling carbon fiber through a
glass pipette using a Sutter P-97 puller to form a glass seal. The fiber was
then cut to ⬃100 –120 m past the seal. The potential at the working
electrode was held at ⫺0.4 V versus an Ag/AgCl reference electrode, then
ramped to 1.3 V and then back to ⫺0.4 V at 400 V/s at a rate of 10 Hz. A
single biphasic electric pulse was applied using a platinum/iridium parallel bipolar stimulating electrode (FHC) at 300 –500 A to evoke dopamine release. Each animal contributed 1–3 slices to each group. Each slice
was counted as an individual replicate.
In vivo voltammetry. Mice were anesthetized with 1.5 g/kg urethane.
Sixty minutes later, depth of anesthesia was confirmed and mice were
mounted on a model 900 stereotaxic alignment system (David Kopf
Instruments). A carbon fiber microelectrode (manufactured as described above) was implanted in the NAc (anteroposterior 1.52 mm,
mediolateral ⫾1.15 mm, dorsoventral ⫺3.9 to 4.3 mm from bregma)
and a silver chloride reference electrode was implanted contralaterally. Bipolar parallel stimulation electrodes (Plastics One) were implanted either in the medial forebrain bundle (MFB) (anteroposterior
⫺2.40 mm, mediolateral ⫾1.10 mm, dorsoventral ⫺4.5 to 5.20 mm
from bregma) or the pedunculopontine tegmental area (PPTg) (anteroposterior ⫺0.68 mm from, mediolateral ⫾0.70 mm, dorsoventral ⫺2.50 to 3.20 mm from bregma). For MFB recordings, a stimulus
of 6 pulses was applied at 30 Hz and 300 A to evoke dopamine
release. For PPTg recordings, a stimulus of 30 pulses was applied at 60
Hz and 150 A. Stimuli were applied every 300 s. After 60 min, mice
were injected with U50,488 (5 mg/kg, i.p.) and recording continued
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-16.7 nA
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2014).
In vivo electrophysiology. As previously deBaseline
c
scribed (Zweifel et al., 2011), microdrives
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were fabricated in house using 16-channel
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electrode interface boards (EIB-16; Neuralynx) and tetrodes made from 0.00099-inch4 nA
diameter tungsten wire (California Fine
2s
Wire). Mice were stereotaxically implanted
KOR lox/lox
KOR CKODAT
KOR CKOPet
into the VTA using coordinates x ⫽ ⫺3.25
mm from bregma, y ⫽ 0.05 mm from midd
e
norBNI
line, and z ⫽ ⫺4.5 mm from dura. Two
U69,593
weeks following recovery, mice were
screened for putative dopamine neurons.
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20
*** ***
During recording sessions, data were ac0
0
quired by connecting mice to a 16-channel
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Medusa Preamplifier. Signals were filtered at
KOR lox/lox
300 –5000 Hz using a RZ5 Signal Processor
-40
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(Tucker-Davis Technologies). Tetrodes were
-60
-60
lowered daily in ⬃40 m increments until
KOR CKOPet
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Once recording began, a 10 min baseline period was acquired followed by administra- Figure 1. Conditional knock-out of KOR from either dopaminergic or serotonergic neurons blocks U50,488-CPA, but only KOR
tion of drugs. Putative dopamine neurons CKO from dopaminergic neurons blocks inhibition of dopamine release. a, Conditioned place aversion following U50,488 (5 mg/kg)
from N ⫽ 4 control and N ⫽ 5 p38␣ MAPK was evident in wild-type and KOR lox/lox littermates but was blocked by conditional KOR gene deletion in either dopaminergic (CKO
CKO mice were identified by firing rate (⬍12 KOR DAT) or serotonergic (CKO KOR Pet) neurons. Place preference scores showed that both CKO KOR DAT and CKO KOR Pet lack
Hz) and by sensitivity to quinpirole (a reduc- U50,488 CPA relative to KOR lox/lox littermates (n ⫽ 9 –22). *p ⬍ 0.05 (Bonferroni post hoc after one-way ANOVA). **p ⬍ 0.01
tion in firing rate to ⱕ50% of baseline). (Bonferroni post hoc after one-way ANOVA). b, Representative image showing analysis of slice FSCV data. Bottom, Heat map
Quinpirole-sensitive firing rates were calcu- represents current generated by oxidation and reduction at the site of the working electrode during application of the triangle
lated from a 10 min window starting 3 min waveform. Top, Current ⫻ time plot shows evoked dopamine release and uptake. Orange dashed line indicates magnitude of peak
after injection. Once dopaminergic cells current, which was recorded for each stimulation event (marked by arrow: 1 pulse, 300 –500 A). Inset, Cyclic voltammagram
were identified, cell activity was recorded from the time of peak current confirms that the current recorded was induced by oxidation and reduction of dopamine. Calibration:
over 4 consecutive days. One day following 2 nA, 0.1 V. c, Left, Diagram depicting placement of bipolar stimulating electrode (red) and recording electrode (blue) during slice
identification of quipirole-sensitive neu- FSCV experiments (modified from Paxinos and Franklin, 2008). Right, Representative traces showing raw current responses of
rons, activity was recorded during a 10 min KOR lox/lox, KOR CKO DAT, and KOR CKO Pet to 1 M U69,593 (green) and 1 M norBNI (purple). Calibration: 4 nA, 2 s. Arrow indicates
baseline followed by two successive injec- stimulation timing. d, Change from baseline locally stimulated peak [DA] during baseline and following administration of 1 M
tions of saline and 50 min of additional re- U69,593 and 1 M norBNI. Each drug was bath-applied during the interval signified by the bar. e, Summary data of percentage
cording following each injection for a total
change in [DA] from baseline shows that KOR CKO DAT significantly blocked U69,593-induced inhibition of evoked dopamine
recording session of 110 min. On the second,
release relative to KOR lox/lox littermates, whereas inhibition of DA release was unaltered in KOR CKO Pet (n ⫽ 4 or 5 slices from 2 or
third, and fourth day, mice were adminis3 animals). ***p ⬍ 0.001 (Bonferroni post hoc after one-way ANOVA). All graphs represent data as mean ⫾ SEM.
tered saline (50 min recording) followed by
U50,488 (5 mg/kg). For nor-binaltorAnalysis. Data were compiled in Microsoft Excel, and data analyses were
phimine dihydrochloride (norBNI) pretreatment, five mice were inperformed
in Prism 5.01 for Windows (GraphPad). CPP data were analyzed
jected with norBNI (10 mg/kg) 50 min before U50,488 injection.
by Student’s t test or one-way ANOVA where appropriate. Locomotor, tailSingle units were isolated by cluster analysis using Offline Sorter
flick analgesia, and voltammetry data were analyzed using two-way
software (Plexon), and clustered waveforms were analyzed using
repeated-measures ANOVA. For in vivo voltammetry, the last six stimuli of
MATLAB software (The MathWorks).
each treatment (baseline vs U50,488) were averaged for each animal, and this
Drugs. (⫾) U50,488H, (⫾) U69,593, nor-binaltorphimine dihydroaverage was used for statistical comparisons. For in vitro voltammetry, the
chloride (norBNI), and cocaine hydrochloride were provided by the
last four stimuli of each treatment (baseline, SB203580/vehicle, U69,593, and
National Institute of Drug Abuse Drug Supply Program. SB203580
norBNI) were averaged for each slice. When ANOVA revealed statistical
was obtained from Millipore. Quinpirole and urethane were obtained
significance, Bonferroni post hoc analyses were applied where approfrom Sigma-Aldrich. Sodium pentobarbital and Beuthanasia
priate; in certain cases, Bonferroni post hoc analyses were applied after
Special-D were obtained from University of Washington Medical
no interaction was seen to confirm negative results. Data are preCenter Drug Services. All drugs were dissolved in saline for use in vivo
sented as mean ⫾ SEM. Significance was set at p ⬍ 0.05.
or aCSF for use in vitro.

Ehrich et al. • KOR-Induced Aversion Requires p38 MAPK Activation

0
-50
-100
-150

10000
8000

Saline
norBNI
VTA injection
Saline
U50,488

d

***

6000
4000
2000
0
KOR KOR KOR KSA eGFP
+/+ -/- VTA viral injection

6

*

*

***

Tail flick latency (s)

50

4
2
0

*

100
50
0
-50
-100
-150
-200 KOR KOR KOR KSA eGFP
+/+
-/VTA viral injection
Baseline
Baseline
U50,488 e
U50,488
6

U50,488 preference
(post - pre, s)

*

100

c

Distance traveled (cm)

b

Tail flick latency (s)

U50,488 preference
(post - pre, s)

a

J. Neurosci., September 16, 2015 • 35(37):12917–12931 • 12921

KOR KOR KOR KSA eGFP
+/+ -/- VTA viral injection

***
4
2
0

KOR (DRN)

f
KOR +/+
No Virus

KOR-ir
TH-ir
KOR -/No Virus

KOR -/KOR in VTA

KOR -/KSA in VTA

50 m
KOR -/KOR in DRN
SNC

ml
VTA

SNR
SNC

Figure 2. KOR activation within the VTA is both necessary and sufficient for U50,488-induced CPA. a, Local inactivation of KOR
by bilateral stereotaxic injection of norBNI into the VTA blocked U50,488 (5 mg/kg) induced CPA. Place preference scores for WT
mice injected with either saline or 2.5 g/l norBNI in the VTA before U50,488 conditioning (n ⫽ 8). *p ⬍ 0.05, saline versus
norBNI (t test). b, U50,488 produced significant place aversion in wild-type (KOR ⫹/⫹) mice, but not in KOR ⫺/⫺ knock-out mice.
Right, KOR ⫺/⫺ mice were injected with lenti-KOR, lenti-KSA, or lenti-eGFP in the VTA before U50,488 CPA. Lenti-KOR in the VTA
significantly restored U50,488 CPA, whereas neither lenti-KSA nor lenti-eGFP did. Left, *p ⬍ 0.05 (t test). Right, *p ⬍ 0.05
(Bonferroni post hoc analysis after one-way ANOVA). n ⫽ 11–19. c, U50,488 (10 mg/kg) significantly reduced locomotor activity
compared with saline injection in wild-type KOR ⫹/⫹ mice, but not in KOR ⫺/⫺ or in mice receiving lenti-viral injections in VTA
(n ⫽ 6 –11). ***p ⬍ 0.001 (Bonferroni post hoc analysis after two-way ANOVA). x-axis labels are the same groups as in b. d,
Similarly, U50,488 significantly reduced tail-withdrawal latencies compared with saline injection in wild-type KOR ⫹/⫹ mice, but
not in KOR ⫺/⫺ or in mice receiving lenti-viral injections in VTA. Withdrawal latencies were recorded before and 30 min after 15
mg/kg U50,488 (n ⫽ 11–19). ***p ⬍ 0.001 (Bonferroni post hoc after two-way ANOVA). x-axis labels are the same groups as in
b. e, In contrast, latency to tail-flick was significantly increased by 15 mg/kg U50,488 in KOR ⫺/⫺ mice injected with lenti-KOR in
DRN (n ⫽ 13). ***p ⬍ 0.001 (paired t test). f, Representative IHC images showing restoration of KOR immunoreactivity (red)
in TH-ir (green) neurons of the VTA after injection of lenti-KOR or lenti-KSA into the VTA of KOR ⫺/⫺ mice, but not after injection
of lenti-KOR into the DRN. Note the presence of double-labeled neurons (yellow) in uninjected KOR ⫹/⫹ and in sections from
KOR ⫺/⫺ mice injected with either lenti-KOR or lenti-KSA in VTA. Bottom-right inset (red rectangle), Location of the section of the
parabrachial pigmented nucleus of the VTA from which images were taken (modified from Paxinos and Franklin, 2008).

Results
KOR activation in both dopamine and serotonin neurons is
required for place aversion
To compare the roles of KOR activation in dopamine neurons
and serotonin neurons in aversion, we generated a conditional
knock-out of KOR in dopaminergic (DAT-Cre-expressing) neurons and serotonergic (ePet-Cre-expressing) neurons using a
Cre-induced excision of a floxed KOR allele (KOR CKO DAT and
KOR CKO Pet, respectively). Male KOR lox/lox littermate controls
from both colonies showed CPA to U50,488, whereas neither

KOR CKO DAT nor KOR CKO Pet showed
U50,488 CPA (Fig. 1a; one-way ANOVA,
F(2,40) ⫽ 7.338, p ⬍ 0.01; post hoc analyses:
KOR lox/lox vs KOR CKO DAT, t(40) ⫽
2.340, p ⬍ 0.05; KOR lox/lox vs KOR
CKO Pet, t(40) ⫽ 3.623, p ⬍ 0.01). These
results demonstrated that selective genetic
ablation of KOR within either class of
neurons was sufficient to block U50,488
CPA.
KOR CKO from dopaminergic neurons,
but not serotonergic neurons, blocks
inhibition of dopamine signaling
Prior studies concluded that the aversion response to KOR activation was
caused by inhibition of dopamine release in the NAc (Shippenberg et al.,
1993), which requires expression of
KOR by dopamine neurons (Chefer et
al., 2013; Tejeda et al., 2013). To determine whether KOR CKO Pet blocked
U50,488 CPA by altering the response of
NAc dopamine signaling to KOR activation, we used FSCV to record evoked
dopamine release from midbrain slices
containing the NAc (Fig. 1b). The KOR
agonist U69,593 (1 M) produced robust inhibition of evoked dopamine in
midbrain slices from KOR lox/lox and
KOR CKO Pet mice (52.7% and 54.5%
below baseline, respectively). This inhibition was reversed upon washout or
addition of the KOR antagonist norBNI
(1 M) (Fig. 1c– e). In contrast, evoked
dopamine response in slices from KOR
CKO DAT showed no significant change
in the presence of either drug (Fig.
1c– e). A two-way repeated-measures
ANOVA showed a significant interaction (F(2,11) ⫽ 18.10, p ⬍ 0.001). Further, post hoc analyses demonstrated
that both KOR lox/lox (t(11) ⫽ 4.309,
p ⬍ 0.001) and KOR CKO Pet (t(11) ⫽
4.242, p ⬍ 0.001) mice showed significant inhibition of dopamine release relative to KOR CKO DAT mice after
U69,593. Thus, while KOR excision
from either dopamine neurons or serotonin neurons blocked CPA, KOR excision from serotonin neurons blocked
CPA despite continued inhibition of
evoked NAc dopamine release.

KOR activation in the VTA is required for place aversion
Local inactivation of KOR by stereotaxic injection of the longacting KOR antagonist norBNI (2.5 g/l) into the VTA blocked
U50,488 CPA (Fig. 2a; unpaired t test, t(7) ⫽ 3.306, p ⬍ 0.05,
compared with mice injected with an equal volume of saline in
VTA). norBNI has previously been demonstrated to block
KOR activation up to 21 d after administration (Bruchas et al.,
2007b). This result demonstrated that activation of KORs
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Figure 3. KOR activation selectively in VTA dopamine neurons is sufficient for KOR CPA. a, Schematic represents the design of AAV-DIO viral construct, along with inversion of KOR-GFP/KSA-GFP
gene and excision of loxp/lox2722 sites in the presence of Cre. b, Representative IHC images showing DIO-KSA-GFP selectively expressed in VTA TH-ir neurons in DAT Cre/⫹ but not DAT ⫹/⫹ animals
after VTA injection: red represents TH-r; green represents GFP-ir; yellow represents colabeling. c, Cell counts after VTA injection of DIO-KOR-GFP or DIO-KSA-GFP show a significant increase in cells
double-labeled with TH-ir and GFP-ir in DAT Cre/⫹ animals relative to DAT ⫹/⫹ littermates (n ⫽ 7–16). ***p ⬍ 0.001 (Bonferroni post hoc after two-way ANOVA). d, U50,488-CPA was selectively
restored after injection of DIO-KOR-GFP into the VTA of DAT Cre/⫹, KOR ⫺/⫺ mice, but not after injection of DIO-KSA-GFP (n ⫽ 14 –17). **p ⬍ 0.01 (t test).

within the VTA was necessary for U50,488 CPA. To assess
sufficiency, we next injected KOR ⫺/⫺ (Oprk1⫺/⫺) mice with a
lentiviral vector directing expression of the wild-type KOR
(lenti-KOR) (viral design as previously described; Land et al.,
2008). Lenti-KOR injection in the VTA selectively restored the
aversive properties of KOR activation (one-way ANOVA,
F(2,33) ⫽ 5.140, p ⬍ 0.05) (Fig. 2b). In contrast, uninjected
KOR ⫺/⫺ or mice injected lentivirus encoding enhanced green
fluorescent protein alone (lenti-eGFP) did not develop
U50,488 CPA (Fig. 2b). A different group of KOR ⫺/⫺ mice
were injected with a lentiviral vector directing expression of

KOR with a serine to alanine substitution at serine 369 (lentiKSA). Phosphorylation of KOR by GRK3 at serine 369 is necessary for arrestin-dependent activation of p38 MAPK while
allowing for arrestin-independent signaling, such as activation of extracellular signal-regulated kinase (ERK1/2) (Bruchas et al., 2006). KOR ⫺/⫺ mice expressing lenti-KSA (t(33) ⫽
2.891, p ⬍ 0.05) did not develop U50,488 aversion (Fig. 2b).
KOR ⫺/⫺ mice injected with lenti-KOR in the DRN as a positive control also showed a restoration of U50,488 CPA (data
not shown, one-sample t test, p ⬍ 0.01, t(14) ⫽ 3.538), replicating our previous findings (Land et al., 2008).
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strated that only KOR ⫹/⫹ mice showed a significant increase in
their tail-flick latency 30 min after injection with U50,488 (15
mg/kg, i.p.) (KOR ⫹/⫹, p ⬍ 0.001). Neither KOR ⫺/⫺ mice without viral injection nor any group receiving lentiviral injections
into the VTA showed an effect of U50,488 ( p ⬎ 0.05, all groups)
(Fig. 2d). As a positive control, we performed a tail-flick analgesia
test on KOR ⫺/⫺ mice that had received lenti-KOR injected into
the DRN. A paired t test showed that the lenti-KOR injection into
the DRN restored U50,488-induced analgesia in these mice
(t(12) ⫽ 4.409, p ⬍ 0.001) (Fig. 2e). This demonstrated that the
restoration of U50,488 CPA in lenti-KOR VTA mice was not due
to viral diffusion to the nearby DRN.
After the behavioral analyses were concluded, mice were
killed, and immunohistochemistry (IHC) was performed to assess KOR expression in the VTA. KOR-immunoreactivity (ir)
was evident in the VTA of wild-type mice, as well as KOR ⫺/⫺
mice injected with lenti-KOR or lenti-KSA in the VTA, but not in
uninjected KOR ⫺/⫺ mice (Fig. 2f ). KOR-ir was not evident in the
VTA after lenti-KOR injection into the DRN (Fig. 2g), thus further demonstrating that the aversion seen after DRN injection
was not due to viral diffusion to the VTA. KOR expression was
not seen outside of the VTA in mice injected intra-VTA with
either lenti-KSA or lenti-KOR (data not shown).

Figure 4. ROSA-YFP reporter shows that DAT-Cre selectively expresses in dopaminergic neurons. a, Representative IHC images showing that YFP-ir in an animal with DAT-Cre-directed
ROSA-YFP expression extensively colabels with TH-ir throughout the VTA, yet YFP expression
was absent in sections from mice lacking Cre: green represents YFP-ir; red represents TH-ir;
yellow represents double-label. b, Representative IHC images showing that YFP-ir in sections
from an animal with DAT-Cre-directed YFP expression in the VTA does not colabel with GAD67ir. Arrows point to GABAergic neurons. c, Representative IHC images showing that YFP-ir in an
animal with DAT-Cre-directed YFP expression in the DRN colabels with TH-ir but not TPH-ir. Left
panel, Imaged section of the DRN (modified from Paxinos and Franklin, 2008).

Systemic injection of 10 mg/kg U50,488 induces locomotor
hypoactivity, an effect that is mediated by KOR actions at substantia nigra dopamine neurons (Schnur and Walker, 1990). For
2 d following the CPA post-test, a subset of animals were alternately injected with either saline or U50,488 (10 mg/kg, i.p.) and
allowed to freely explore the CPP chambers. Two-way ANOVA
showed a significant interaction (F(4,37) ⫽ 8.480, p ⬍ 0.0001), and
KOR ⫹/⫹ mice showed a significant inhibition in locomotor activity after U50,488 relative to saline (t(37) ⫽ 7.259, p ⬍ 0.001).
Neither KOR ⫺/⫺ mice nor any virally injected group showed an
effect of U50,488 on locomotor activity ( p ⬎ 0.05) (Fig. 2c),
demonstrating that the restoration of KOR expression was
restricted.
We previously reported that injection of lenti-KOR or lentiKSA into the DRN restored U50,488-induced analgesia, leading
to an increase in warm water tail-flick latency (Land et al., 2008).
Two-way ANOVA showed a significant interaction (F(4,57) ⫽
8.827, p ⬍ 0.0001), and subsequent post hoc analysis demon-

Selective restoration of KOR activation to VTA dopamine
neurons of KOR ⴚ/ⴚ mice rescues aversion in a
phosphorylation-dependent manner
Although the previous experiment demonstrated that KOR activation and phosphorylation within VTA neurons was sufficient
to support U50,488 CPA, it did not clarify which cell types are
required. To determine whether KOR expression within dopaminergic neurons of the VTA alone was sufficient to support KORCPA, we developed an adeno-associated double-floxed inverse
open reading frame (AAV-DIO) viral construct (Cardin et al.,
2009) directing expression of GFP-tagged KOR or KSA selectively
in Cre-expressing neurons (Fig. 3a; DIO-KOR-GFP or DIOKSA-GFP). The number of cells showing colocalization between
GFP-ir and immunoreactivity for tyrosine hydroxylase (TH-ir), a
selective marker for dopamine neurons, was significantly increased in DAT Cre/⫹ mice relative to DAT ⫹/⫹ mice (Fig. 3b,c;
two-way ANOVA, main effect of genotype, F(1,43) ⫽ 110.7, p ⬍
0.0001), demonstrating selectivity of expression. Although WT
control mice showed a normal CPA to U50,488, DAT Cre/⫹
KOR ⫺/⫺ mice showed U50,488 CPA after intra-VTA injection
with DIO-KOR-GFP but not DIO-KSA-GFP (Fig. 3d; unpaired t
test, t(29) ⫽ 2.767, p ⬍ 0.01). This demonstrates that KOR activation in VTA dopamine neurons alone is sufficient to support
CPA, but this requires an intact GRK3 phosphorylation site.
Expression of p38␣ MAPK in dopamine neurons is selectively
required for KOR CPA
To test the hypothesis that p38 MAPK activation in dopaminergic
neurons is required for the aversive properties of KOR activation,
we generated a conditional knock-out of p38␣ MAPK in DATexpressing neurons, using a Cre-induced recombination of a
floxed p38␣ MAPK allele (Bruchas et al., 2011). A subset of animals carried a floxed-STOP ROSA-YFP reporter allele to ensure
that Cre-induced recombination only occurred in dopamine
neurons. Subsequent IHC demonstrated that YFP highly coexpressed with tyrosine hydroxylase (TH-ir) within the VTA only in
Cre-expressing animals (Fig. 4a) but did not colabel with the 67
kDa isoform of glutamic acid decarboxylase, a marker for
GABAergic somata (Fig. 4b). The DRN also contains dopaminer-
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2.366, p ⬍ 0.05; post hoc vs Cre ⌬,
t(31) ⫽ 2.496, p ⬍ 0.05) (Fig. 5a). These
dopaminergic neurons selectively blocks the aversive properties of KOR
results suggest that the aversive proper- Figure 5. Conditional knock-out of p38 MAPK from
activation. a, Preference scores show that p38␣ CKO DAT mice do not show U50,488 CPA, unlike WT and Cre ⌬ littermates (n ⫽
ties of KOR activation are dependent on 12–20). *p ⬍ 0.05 (Bonferroni post hoc after one-way ANOVA). b, Fall latency for each trial from rotarod performance assay shows
the expression of p38␣ MAPK in dopa- no effect of p38␣ CKO DAT (n ⫽ 10 –16). c, WT, Cre ⌬, and p38␣ CKO DAT mice all show normal cocaine CPP (n ⫽ 8 –11). d, WT, Cre
minergic neurons.
⌬, and p38␣ CKO DAT mice all show normal acute locomotor sensitization to cocaine (n ⫽ 8 –11). **p ⬍ 0.01 (Bonferroni post hoc
We next tested mice with repeated ex- after two-way ANOVA). ***p ⬍ 0.001 (Bonferroni post hoc after two-way ANOVA).
posure to the rotarod performance assay,
a dopamine-dependent test of motor coneurons (Borgland et al., 2006), these results further confirm that
ordination in which mice learn to avoid a negative outcome over
effects of p38 inactivation are specific to aversion relating to KOR
repeated trials (Zhou and Palmiter, 1995). p38␣ CKO DAT mice
activation and do not appear to reflect general deficits in dopashowed no deficit in this task, as demonstrated by a statistically
mine neuron function.
significant main effect of trial (Fig. 5b; two-way repeatedmeasures ANOVA, F(8,36) ⫽ 55.55, p ⬍ 0.0001) and no effect of
Conditional knock-out of p38␣ from dopamine neurons fails
genotype (F(2,36) ⫽ 1.059, p ⫽ 0.3573). Although a statistically
to alter KOR-induced inhibition of dopamine release in vivo
significant interaction was seen (F(16,36) ⫽ 2.098, p ⬍ 0.01), post
To determine whether p38␣ MAPK was also required for the
inhibition of dopamine release, we used FSCV to measure subhoc analyses showed no significant difference between the perforsecond changes in the release of dopamine in anesthetized mice
mance of p38␣ CKO DAT mice and WT ( p ⬎ 0.05) or Cre ⌬ ( p ⬎
0.05) mice during any trial. Indeed, p38␣ CKO DAT mice showed
(Fig. 6a). U50,488 (5 mg/kg, i.p.) inhibited dopamine release
evoked by MFB stimulation. U50,488 reduced evoked dopamine
a slight trend toward improved performance relative to WT, sugrelease equivalently in both NAc core (54.5 ⫾ 4.2% inhibition
gesting that p38 inactivation in dopamine neurons does not disfrom baseline) and shell (50.7 ⫾ 2.3% inhibition from baseline)
rupt basic motor learning and therefore is not grossly altering
of wild-type mice, but did not do so in KOR ⫺/⫺ mice (Fig. 6b;
dopamine neuron function.
two-way ANOVA, main effect of genotype: F(1,16) ⫽ 205.3, p ⬍
To determine whether conditional knock-out of p38␣ af0.0001).
fected Pavlovian contextual learning, we measured cocaine CPP.
Because there was no trend toward a main effect of NAc subp38␣ CKO DAT mice developed robust cocaine CPP, and there
was no significant difference between the three genotypes (oneregion on the inhibition of dopamine release (F(1,16) ⫽ 0.9631,
p ⫽ 0.3410) and no interaction (F(1,16) ⫽ 0.006200, p ⫽ 0.9382),
way ANOVA, F(2,25) ⫽ 1.385, p ⫽ 0.2688) (Fig. 5c). Locomotor
activity was recorded and analyzed during the cocaine conditiontime-resolved data collected from the NAc core and shell were
ing sessions, and significant locomotor sensitization was evident
collapsed together for comparison between MFB and PPTg stimin all three genotypes (Fig. 5d), as demonstrated by a main effect
ulation. MFB stimulation allows for direct stimulation of the
of training session (F(1,28) ⫽ 52.12, p ⬍ 0.0001), no interaction
fibers projecting to the NAc and minimizes the potential impact
(F(2,28) ⫽ 0.1836, p ⫽ 0.8333) and no effect of genotype (F(2,28) ⫽
of somatodendritic KOR activation, whereas PPTg stimulation
1.314, p ⫽ 0.2849). Further, post hoc analyses for all groups
synaptically activates VTA neurons (Zweifel et al., 2009) and may
showed a statistically significant increase in locomotor activity on
reveal somatodendritic effects of KOR activation on dopamine
the second day of cocaine administration relative to the first (WT:
release in the NAc (Ford et al., 2006, 2007; Margolis et al., 2006;
Ehrich et al., 2014). Positioning of the stimulating electrodes as
t(28) ⫽ 3.867, p ⬍ 0.01; Cre ⌬: t(28) ⫽ 3.863, p ⬍ 0.01; p38␣
CKO DAT: t(28) ⫽ 4.808, p ⬍ 0.001). Because acute sensitization to
shown (Fig. 6c) resulted in robust dopamine signal following
either MFB or PPTg stimulation (Fig. 6d,e, respectively, inset).
the locomotor effects of cocaine has been hypothesized to be
mediated by induction of glutamatergic LTP in dopaminergic
Release evoked by either MFB or PPTg stimulation was signifi-
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Given the role of p38 MAPK in aversion
and the prediction that the inhibition of
dopamine release should be intrinsically
aversive (Wise and Bozarth, 1982; Shippenberg et al., 1993; Di Chiara and Imperato, 2008; Chefer et al., 2013; Tejeda et
al., 2013), the lack of effect of p38␣ deletion on evoked dopamine release was a
surprise. This suggested that the aversive
effects of KOR activation were not caused
by either presynaptic or somatic inhibition of dopamine release within the NAc
and is consistent with our observations
that KOR-mediated aversion through serotonergic neurons is independent from
inhibition of dopamine release.
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0.05
the reversal of inhibition by norBNI
-80
0.00
(main effect of KOR drug: F(2,14) ⫽ 51.95;
DAT
WT
Cre
p38 CKO
MFB
PPTg
p ⬍ 0.0001; no interaction: F(2,14) ⫽ 1.067;
Genotype
Stimulation site
p ⫽ 0.3576). Despite the lack of a signifiFigure 6. Conditional knock-out of p38␣ MAPK from dopaminergic neurons fails to alter inhibition of dopamine release by U50,488 cant interaction, a post hoc was performed
recorded in vivo. a, Representative images demonstrating analysis of FSCV data before and after administration of U50,488. Bottom, Heat to confirm that SB203580 had no effect on
maps represent current generated by oxidation and reduction at the site of the working electrode during application of the triangle U69,593-induced inhibition of dopamine
waveform. Red line indicates time of MFB stimulation (6 pulses at 30 Hz, 300 A), Middle, Current ⫻ time plot shows evoked dopamine release (t(14) ⫽ 0.7348, p ⬎ 0.05). To derelease and uptake. Orange dashed lines indicate magnitude of peak current, which was recorded following stimulation. Top, Cyclic termine whether SB203580 had any effect
voltammagram from the time of peak current confirms that the current recorded was induced by oxidation and reduction of dopamine. b, on the velocity of the inhibition of dopaChangefrombaselineMFB-stimulatedpeak[DA]afteradministrationofU50,488inKOR ⫹/⫹ andKOR ⫺/⫺ mice,asrecordedfromtheNAc mine release, we analyzed the slope of the
coreandshell.n⫽4 – 6.***p⬍0.001(Bonferroniposthocaftertwo-wayANOVA).c,DiagramillustratingstimulationsitesforMFB-and
linear phase during U69,593 onset and
PPTg-evokeddopaminerelease.d,e,RepresentativetracesshowingrawcurrentresponsesofMFB-stimulated(d)andPPTg-stimulated(e)
found no difference between the two (data
DAT
dopamine recorded in WT, Cre ⌬, and p38␣ CKO to 5 mg/kg U50,488 (green). Calibration: 2 nA, 1 s. Red line indicates stimulation. f,
ChangefrombaselineMFB-stimulatedpeak[DA]afteradministrationofU50,488(markedbyarrow)inWT,Cre⌬,andp38␣ CKO DAT mice. not shown: t test, t(14) ⫽ 0.1010,
g, Change from baseline PPTg-stimulated peak [DA] after administration of U50,488 (marked by arrow) in WT, Cre ⌬, and p38␣ CKO DAT p ⫽ 0.9210; vehicle ⫽ ⫺6.0 ⫾ 2.1,
mice.Inset,PPTg-stimulateddopaminereleasebeforeandafteradministrationofU50,488.h,Summarydatashowthatp38␣ CKO DAT fails SB203580 ⫽ ⫺6.2 ⫾ 1.5).
Because both KOR activation and dito alter U50,488-induced inhibition of dopamine relative to WT and Cre ⌬ littermates (n ⫽ 5–16). i, Summary data show that U50,488
does not significantly alter t1/2 in WT, Cre ⌬, or p38␣ CKO DAT mice. n ⫽ 5–16. n.s. (p ⬎ 0.05, Bonferroni post hoc analysis after one-way rect p38 MAPK activation by anisomyANOVA confirmed the lack of statistical significance).
cin have been shown to alter the rate of
dopamine uptake (Thompson et al.,
2000; Zhu et al., 2005), we analyzed the half-life (t1/2) of recantly inhibited by U50,488 (5 mg/kg, i.p.); however, conditional
leased dopamine to determine whether there was any effect of
knock-out of p38␣ from dopamine neurons did not affect
U50,488-induced inhibition of dopamine release following either
either p38 MAPK inhibition or KOR activation in this assay
MFB (Fig. 6d; unpaired t test, t(14) ⫽ 0.3018, p ⫽ 0.7673) or PPTg
(Fig. 7c). No effect of U69,593 was found on t1/2 of released
(Fig. 6e; unpaired t test, t(18) ⫽ 1.649, p ⫽ 0.1166) stimulation.
dopamine (no main effect of KOR drug: F(2,14) ⫽ 1.018, p ⫽
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Figure 7. Pharmacological inhibition of p38 MAPK by SB203580 fails to alter KOR-mediated inhibition of dopamine release recorded in the nucleus accumbens of a mid-brain slice. a, Change from
baseline locally stimulated peak [DA] during baseline and following administration of 10 M SB203580 or aCSF vehicle, 1 M U69,593 and 1 M norBNI. Each drug was bath-applied during the
interval signified by the bar. Inset, Diagram represents placement of bipolar stimulating electrode (red) and recording electrode (blue) during slice FSCV experiments (modified from Paxinos and
Franklin, 2008). b, Summary data show that the p38 inhibitor SB203580 (10 M) did not significantly affect U69,593-induced inhibition of dopamine release (n ⫽ 8 slices from 7 animals) (n.s., p ⬎
0.05, Bonferroni post hoc after two-way repeated-measures ANOVA), despite lack of interaction. Inset, Locally stimulated dopamine release during administration of SB203580 or vehicle, during
baseline (aCSF), U69,593, or U69,594 with norBNI. Calibration: 1 s, 2 nA. Arrow indicates stimulation. c, Clearance rates (T1/2) of evoked dopamine from peak during administration of 10 M
SB203580 or aCSF vehicle, 1 M U69,593, and 1 M norBNI (n ⫽ 8 slices from 7 animals) (n.s., p ⬎ 0.05, Bonferroni post hoc analysis after two-way repeated-measures ANOVA confirmed lack of
statistical difference).

0.3745), which was also unaltered by
SB203580 (main effect: F(2,14) ⫽ 0.0003,
p ⫽ 0.9871). Despite the lack of a significant interaction, two post hoc analyses
were performed to confirm that
SB203580 had no effect on dopamine
uptake either with or without the presence of U69,593 (SB203580 or vehicle
alone: t(14) ⫽ 0.6755, p ⬎ 0.05; U69,593:
t(14) ⫽ 0.9288, p ⬎ 0.05). These results
indicate that the KOR-induced inhibition of dopamine release in the NAc did
not require p38 activation either in vivo
or in vitro.
In vivo recording of VTA neuron firing
rates in freely moving mice
The lack of effect on evoked dopamine
release suggested that KOR activation of
p38␣ MAPK produced aversion by a different effect on VTA neuron excitability. Prior in vitro electrophysiological
studies have demonstrated that acute
KOR activation inhibits both presynaptic excitatory and inhibitory synaptic inputs to VTA dopamine neurons, as well Figure 8. In vivo recording of VTA dopamine neurons in wild-type littermate and p38␣ CKO DAT mice shows no significant
postsynaptically reducing firing rates by differences in baseline firing properties. A, Brain atlas diagram illustrating placement of tetrodes for control (black) and p38␣
activating outward potassium currents CKO DAT (CKO) (red) mice. B, Average waveform of neurons responsive to quinpirole in control (black, N ⫽ 14) and CKO (red, N ⫽
(Margolis et al., 2003, 2006; Ford et al., 8) mice. C, Baseline firing rate of quinpirole-sensitive neurons. D, Baseline burst rate of quinpirole-sensitive neurons. E, Percentage
2006, 2007). How VTA neuronal excit- spikes per burst of quinpirole-sensitive neurons.
ability is affected by repeated KOR activation at the doses and schedules used
putative dopamine cells were identified that displayed an infor conditioned place aversion is not clear from the in vitro
hibitory response to the dopamine D2 receptor agonist quinanalysis. To determine how the dose of U50,488 that promotes
pirole, as previously described (Zweifel et al., 2009, 2011).
conditioned aversion in wild-type mice alters the firing of
Action potential waveforms of putative dopamine neurons
dopamine neurons in a p38-dependent manner, we recorded
and basic firing properties of these cells did not differ between
neural activity in the VTA of wild-type and p38␣ CKO DAT in
control and p38␣ CKO DAT mice (Fig. 8B–E).
unanesthetized, freely behaving mice. Drivable tetrodes were
On day 1, wild-type C57BL/6 male mice (control) and p38␣
implanted daily above the VTA (Fig. 8A) and lowered until
CKO DAT mice (CKO) were injected with saline following a 10

Ehrich et al. • KOR-Induced Aversion Requires p38 MAPK Activation

J. Neurosci., September 16, 2015 • 35(37):12917–12931 • 12927

trol mice (day 2 t(35) ⫽ 2.53, p ⬍ 0.05),
returning to day 1 levels of inhibition on
the third day of U50,488 (Fig. 9 A, C). In
contrast to control mice, p38␣ CKO DAT
mice demonstrated inhibition on day 2
(t(35) ⫽ 2.04, p ⬍ 0.05) and day 3 (t(41) ⫽
2.03, p ⬍ 0.05). p38␣ CKO DAT mice
maintained an increased inhibitory response on day 3, suggesting that p38␣
MAPK activation was responsible for
the adaptation (Fig. 9 B, C). To confirm
the increased inhibitory response of
neurons to a subsequent dose of
U50,488 was dependent on KOR activation, we repeated our recordings in a
separate cohort of control mice but pretreated with the KOR antagonist norBNI (10 mg/kg, i.p.) 50 min before
U50,488 administration on the first day.
Pretreatment with norBNI prevented
the enhanced inhibitory response to
U50,488 on the second day of administration, confirming KOR dependence
(Fig. 9C).
p38 MAPK activation stimulates GIRK
phosphorylation in VTA dopamine
neurons
The change in excitability noted in the
quinpirole-sensitive VTA neurons is consistent with an effect of p38␣ MAPK activation that we previously observed in
DRN neurons (Lemos et al., 2012). KOR
activation increases G-protein-gated inwardly rectifying potassium channel conductance in both DRN and VTA neurons
(Margolis et al., 2003; Ford et al., 2006;
Lemos et al., 2012), and this likely results
in the reduced firing rates of the VTA
neurons. KOR activation of p38 MAPK
results in phosphorylation of these channels, which reduces their conductFigure 9. A, B, Change in firing rate following injection of saline or U50 on consecutive days for control (A) and CKO (B) mice ance (through an enhanced rate of
(control saline, N ⫽ 31; U50 d 1, N ⫽ 21; U50 d 2, N ⫽ 26; U50 d 3, N ⫽ 35; p38␣CKO DAT saline, N ⫽ 33; U50 d 1, N ⫽ 40; U50 deactivation) (Ippolito et al., 2002). Pred 2, N ⫽ 35; U50 d 3, N ⫽ 41). Data are presented as the average change in firing rate (Hz) from a 10 min baseline period. Data are venting this channel phosphorylation by
binned into 10 min blocks. C, Average change in firing rate during the last 40 min following injection of saline or U50,488 across p38␣ CKO would result in the pattern of
groups. *p ⬍ 0.05, relative to corresponding saline (Bonferroni post-test). D, Change in firing rate following injection of U50 on
sustained inhibition evident in the CKO
successive days. Mice were pretreated with an injection of norBNI 50 min before U50 on day 1 (U50 d 1, N ⫽ 22; U50 d 2, N ⫽ 24).
mice on day 3. To test the hypothesis
that KOR activation increases GIRKmin baseline recording period. VTA neurons did not significantly
phosphorylation in VTA neurons, we used a phospho-selective
change their firing rates (Fig. 9 A, B). On the next 3 consecutive
antibody previously shown to detect phospho-tyrosine 12 in Kir
days, mice were injected with U50,488 (5 mg/kg, i.p., U50-1,
3.1 (Ippolito et al., 2005). Treatment with the KOR agonist
U50,488 was shown to increase pY12-Kir 3.1/GIRKp-ir in the
U50-2, U50-3) following a 10 min baseline recording period to
dorsal raphe nucleus in a p38␣-dependent manner (Lemos et al.,
mimic place aversion conditioning. We were surprised to see that
2012).
U50,488 injection did not significantly affect the average firing
In the current study, we examined GIRKp-ir expression in
rate of putative dopamine neurons on the first day of injection in
ROSA26YFP-reporter labeled dopaminergic neurons of the
either control or CKO mice (Fig. 9A–C). On day 1, some cells
increased and some decreased their firing rates (Fig. 9D), which
VTA. In DAT-cre mice, ROSA26YFP expression was restricted to
resulted in no effect overall. However, on day 2 of U50,488, we
dopaminergic neurons of the VTA (Fig. 10A). Basal GIRKp-ir
observed a significant decrease in firing of neurons in both conwas low, but substantially increased following repeated U50,488
trol and p38␣ CKO DAT mice (Fig. 9A–C; repeated-measures
treatment (20 mg/kg i.p., once daily 3 d; Fig. 10A). Basal
GIRKp-ir was also low in VTA sections from p38␣ CKO DAT mice
ANOVA effect of day F(3,253) ⫽ 4.31; p ⬍ 0.01). Enhanced inhibitory responses to U50,488 were a temporary adaptation in conpretreated with saline; however, repeated U50,488 treatment in-
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creased GIRKp-ir only in nondopaminergic neurons (Fig. 10A). The number of
dopaminergic neurons coexpressing
GIRKp-ir was quantified in a blinded
manner (Fig. 10B). The percentage of
GIRKp-positive YFP-positive cells increased in control mice expressing wildtype levels of p38␣ (U50(3d) treated: 63 ⫾
1.5%, saline vehicle (3d): 35 ⫾ 7%). The
U50,488-induced increase in colocalization was not evident in p38␣ CKO DAT
conditional knock-out mice lacking p38␣
in dopaminergic neurons (U50(3d): 39 ⫾
4%, Sal(3d): 32 ⫾ 3%, two-way ANOVA,
F(1,40) ⫽ 4.91, main effect of treatment
p ⫽ 0.0008; genotype p ⫽ 0.0074; interaction p ⫽ 0.0325, Bonferroni post hoc significant (t(40) ⫽ 4.521, p ⬍ 0.001) for
control saline vs control U50, n ⫽ 3 or 4
slices per animal, 2 or 3 animals per group;
Figure 10 A, B). The increase in GIRK
channel phosphorylation by KOR activated p38 is consistent with the suppression of U50,488 inhibitory effects on
dopaminergic neurons firing observed on
day 3, but how that results in CPA is not
yet clear.

A
Control + Sal

Control + U50

p38αCKODAT + Sal

p38αCKODAT + U50

GIRKp-ir
YFP-ir

50 μm

B

Discussion
The principal findings of this study are
that KOR activation of p38 MAPK
within the VTA is required for the aversive properties of KOR activation. Second, the aversive properties of KOR
activation are rescued in KOR ⫺/⫺ mice
by viral restoration of KOR signaling to
VTA dopamine neurons. This restoration is dependent on the phosphorylation of KOR at serine 369, which is
required for p38 activation but not for
activation of ERK (Land et al., 2008). Figure 10. U50,488 increases VTA dopamine neuron GIRKp-ir in a p38␣ MAPK-dependent manner. A, Representative merged
Third, the aversive properties of KOR fluorescent images (40⫻) illustrating the increased amount of GIRKp-ir (green fluorescence) in YFP-reporter-labeled dopamine
activation are dependent on the expres- neurons (red fluorescence) of the VTA following 3 d of U50,488 treatment, giving rise to yellow signal when colocalized. Scale bar,
50 m. B, Quantification of the percentage of YFP-ir putative dopamine neurons of the VTA also positive for GIRKp-ir. In control
sion of p38␣ in dopaminergic neurons,
mice that expressed wild-type levels of p38␣, U50,488 treatment significantly increased the percentage (⫾SEM) of colabeled cells
but the ability of KOR agonists to in- relative to saline vehicle, but this effect of U50 was absent in p38␣CKO DAT mice lacking p38␣ in the YFP-ir cells. ***p ⬍ 0.05,
hibit dopamine release is not dependent interaction (two-way ANOVA). N ⫽ 3 or 4 slices per animal, 2 or 3 animals per group. n.s., Not significant.
on p38 MAPK activation within dopaminergic neurons. Fourth, KOR activapothesis and the data that support it are based on correlation, and
tion has complex, time-dependent effects on VTA neuron
dopamine receptor antagonists are not consistently aversive. The
firing rates, which likely involves p38 MAPK-induced GIRK
hypothesis was driven by the then-prevalent theory that NAc dopaphosphorylation and regulation of excitability. Together,
mine signaling mediated hedonic responses (Wise and Bothese findings suggest that activation of p38 MAPK by KOR in
zarth, 1982), whereas current theories focus more on the role
dopaminergic neurons is required to elicit the aversive propof dopamine signaling in effort (Salamone et al., 2003), reward
erties of KOR agonists, and this process occurs independently
prediction error (Schultz, 1998), reinforcement, or incentive
of KOR’s ability to inhibit dopamine release.
salience
(Montague et al., 2004). The precise role played by
KOR agonists induce dysphoria in humans (Pfeiffer et al., 1986),
reduction
of dopamine in these models is varied and not enaversion in animal models (Shippenberg and Herz, 1986), and inhitirely
clear,
as the experiments performed have focused on
bition of dopamine signaling in the NAc in animal models (Di Chipharmacological or behavioral responses, which increase NAc
ara and Imperato, 1988; Spanagel et al., 1990). As such, it has been
dopamine or directly affect dopamine signaling at or downproposed that these effects are causally related: the aversive properstream of the receptor. We confirm that KOR activation does
ties of KOR agonists are mediated by inhibition of NAc dopamine
inhibit dopamine release in the nucleus accumbens; however,
signaling (Di Chiara and Imperato, 1988; Spanagel et al., 1990;
KOR activation has other actions in the VTA-reward circuit
Tejeda et al., 2012; Carroll and Carlezon, 2013). However, this hy-
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and aversion seems unlikely to be a consequence of a simple
reduction in dopamine transmission.
Reinterpretation of the KOR/dynorphin aversive circuit
Previous experiments have focused on the role of a single monoaminergic circuit as mediating the aversive properties of KOR
activation, predominately via effects on dopamine signaling
(Shippenberg et al., 1993) or via effects on serotonergic signaling
(Land et al., 2008; Bruchas et al., 2011). Other experiments have
focused on the ability of KOR agonists to alter glutamatergic or
GABAergic input onto dopamine neurons (Margolis et al., 2005;
Polter et al., 2014). In wild-type KOR ⫹/⫹ animals, p38 MAPK
activation is necessary in both classes of neurons; further, KOR
activation is necessary in the NAc and DRN (Land et al., 2008;
Bruchas et al., 2011), the VTA (present results), and the mPFC
(Tejeda et al., 2013). This implies the actions of KOR at multiple
sites in the neuronal circuit, requiring either simultaneous or
feedforward activation of KORs and subsequently of p38 MAPK
in an extended circuit to cause aversion. The current results suggest that KOR-mediated aversion is encoded in a complex chain
of neuronal processing events involving multiple brain regions
and that it can be disrupted by breaking any one of the links.
Alternately, KOR activation in different circuits could mediate
different modes of aversion, operationally mediated by disparate
mood states, such as anhedonia, depression, dysphoria, or anxiety. The CPA model used in this and other studies may be incapable
of parsing between these different states. Future experiments could
focus on trying to distinguish between these different states to determine whether each is disparately affected by manipulation of KOR
and p38 MAPK activation in these circuits.
Potential downstream effects of p38 MAPK in
dopaminergic neurons
Although the results presented in this study strongly implicate
p38␣ MAPK-mediated signaling in the VTA dopaminergic neurons, this kinase has a broad range of potential substrates
(Cuadrado and Nebreda, 2010). In serotonergic neurons, KOR
activation of p38␣ MAPK caused translocation of the serotonin
transporter (SERT, SLC6A4 ) from an intracellular, endosomal
compartment to the cell surface to increase the rate of serotonin
reuptake (Bruchas et al., 2011; Schindler et al., 2012). KOR activation of p38␣ MAPK could potentially have affected the DAT
(SLC6A3) because in vivo administration of the  agonist
U69,593 increased dopamine uptake (Thompson et al., 2000);
however, p38 MAPK did not affect dopamine uptake in DATexpressing COS cells (Lin et al., 2003), and we did not observe an
effect of p38 activation on dopamine uptake in the present study.
In contrast, repeated KOR activation produced p38dependent effects on VTA dopamine neuron firing rates in freely
moving, unanesthetized mice in the present study. Prior analyses
using whole-cell voltage-clamp methods demonstrated that KOR
regulates both presynaptic and postsynaptic currents (Margolis
et al., 2003, 2005, 2006; Ford et al., 2006, 2007). Consistent with
the in vitro findings, we observed a complex response following
acute U50,488 administration on day 1, with some cells increasing and some cells decreasing their firing rates. The net effect on
excitability would be expected to depend on the balance between
changes in excitatory, inhibitory, and postsynaptic effects of KOR
activation. This balance shifted on day 2, and the p38␣ MAPKsensitive effect was only evident after repeated KOR stimulation,
which is consistent with prior demonstration that p38 activation
requires sustained KOR activation and arrestin recruitment
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(Bruchas et al., 2006, 2007a, 2011). Although this is somewhat
controversial, KOR activation may acutely increase the
G-protein-gated inwardly rectifying potassium channel in VTA
dopamine cells (Margolis et al., 2003; Ford et al., 2006), as it does
in other neurons. Activation of GIRK would hyperpolarize the
membrane and might contribute to the inhibition of neuronal
firing observed in these freely moving mice. GIRK is a hetrotetrameric potassium channel containing a pair of highly conserved
tyrosine residues in the amino termini of its Kir3.1 and Kir3.4
components (Rogalski et al., 2000). Tyrosine phosphorylation of
these residues inactivates the channel by increasing the rate of
G␤␥ dissociation, as measured in transfected cells (Ippolito et al.,
2002, 2005). Kappa receptor activation of p38 MAPK stimulates
GIRK phosphorylation by activating an src-like kinase in spinal
cord (Rogalski et al., 2000; Clayton et al., 2009), and GIRK currents are similarly inhibited by stress-induced KOR activation of
p38 MAPK in DRN neurons (Lemos et al., 2012). The present
study suggests that stress-induced aversion results from sustained
dynorphin activation of KOR, causing arrestin-dependent p38␣
MAPK phosphorylation of Y12-Kir3.1. The change in postsynaptic effects would alter the balance of excitatory and inhibitory
responses, but exactly how this results in the behavioral response
is not yet clear. What is clear is that p38␣ MAPK signaling downstream of KOR activation impacts the phosphorylation status of
at least one protein, which is likely just a sample of many posttranslational modifications that are altered by activation of this
kinase. Given the broad substrate range of p38␣ MAPK, it is very
likely that the ability of KOR activation to mediate aversive effects
is through changes in the phosphorylation status and function of
these proteins that operate independently of detectable changes
in dopamine release.
These experiments suggest that p38 MAPK in dopamine neurons plays a key role in the aversive properties of KOR. The actions of dynorphin and KOR-induced activation of p38 MAPK
have been proposed to mediate the dysphoric component of
stress (Land et al., 2008) and play a key role in depressive behaviors (Bruchas et al., 2011). Understanding the cellular mechanisms of these behaviors provides novel insights into the stress
response. In addition, results suggesting that the dysphoric effects
of KOR agonists require arrestin-dependent, p38 MAPK signaling supports the hypothesis that a G-protein-biased KOR agonist
might be an analgesic with low abuse potential (Chavkin, 2011).
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